Editas Medicine (EDIT) Retained Earnings (2015 - 2025)
Editas Medicine (EDIT) reported Retained Earnings of -$1.6 billion for Q3 2025, down 15.92% year-over-year from -$1.9 billion in Q3 2024, and down 10819320.0% on a QoQ basis from $15000.0 in Q2 2025.
Editas Medicine (EDIT) has 11 years of Retained Earnings data on file, last reported at -$1.6 billion in Q3 2025.
- Quarterly Retained Earnings fell 15.92% year-over-year to -$1.6 billion in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$1.6 billion (down 15.92% YoY) and the FY2024 annual result came in at -$1.5 billion, down 19.25% from the prior year.
- Retained Earnings retreated to -$1.6 billion in Q3 2025 per EDIT's latest filing, from $15000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $88000.0 in Q1 2025 and bottomed at -$1.6 billion in Q3 2025.
- The 5-year median for Retained Earnings is -$3.4 million (2022), against an average of -$577.2 million.
- The widest annual swing landed in 2022, when Retained Earnings sank 1562400.0%; it then jumped 126.99% in 2025.
- Tracing EDIT's Retained Earnings over 5 years: stood at -$493000.0 in 2021, then tumbled by 218587.83% to -$1.1 billion in 2022, then slipped by 14.21% to -$1.2 billion in 2023, then fell by 19.25% to -$1.5 billion in 2024, then retreated by 10.52% to -$1.6 billion in 2025.
- Per Business Quant, the three latest EDIT Retained Earnings figures stand at -$1.6 billion (Q3 2025), $15000.0 (Q2 2025), and $88000.0 (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.62 Bn |
| Jun 30, 2025 | 15,000.00 |
| Mar 31, 2025 | 88,000.00 |
| Dec 31, 2024 | -1.47 Bn |
| Sep 30, 2024 | -1.40 Bn |
| Jun 30, 2024 | -442,000.00 |
| Mar 31, 2024 | -326,000.00 |
| Dec 31, 2023 | -1.23 Bn |
| Sep 30, 2023 | -1.21 Bn |
| Jun 30, 2023 | -1.17 Bn |
| Mar 31, 2023 | -2.28 Mn |
| Dec 31, 2022 | -1.08 Bn |
| Sep 30, 2022 | -1.00 Bn |
| Jun 30, 2022 | -3.39 Mn |
| Mar 31, 2022 | -2.51 Mn |
| Dec 31, 2021 | -493,000.00 |
| Sep 30, 2021 | -64,000.00 |
| Jun 30, 2021 | -777.20 Mn |
| Mar 31, 2021 | -73,000.00 |
| Dec 31, 2020 | -46,000.00 |
| Sep 30, 2020 | -602.70 Mn |
| Jun 30, 2020 | 183,000.00 |
| Mar 31, 2020 | -586.90 Mn |
| Dec 31, 2019 | -549.22 Mn |
| Sep 30, 2019 | -511.45 Mn |
| Jun 30, 2019 | 45,000.00 |
| Mar 31, 2019 | 29,000.00 |
| Dec 31, 2018 | 803,000.00 |
| Sep 30, 2018 | -391.22 Mn |
| Jun 30, 2018 | -375.99 Mn |
| Mar 31, 2018 | -337.26 Mn |
| Dec 31, 2017 | -305.85 Mn |
| Sep 30, 2017 | -269.66 Mn |
| Jun 30, 2017 | -243.06 Mn |
| Mar 31, 2017 | -216.62 Mn |
| Dec 31, 2016 | -185.53 Mn |
| Sep 30, 2016 | -146.15 Mn |
| Jun 30, 2016 | -125.13 Mn |
| Mar 31, 2016 | -106.09 Mn |
| Dec 31, 2015 | -88.35 Mn |